Lilly To Give High-Risk Alzheimer’s Drug “Every Chance,” says Lechleiter At JP Morgan
This article was originally published in The Pink Sheet Daily
Lilly is relying heavily on biomarkers to help its Alzheimer’s disease-modifying drug solanezumab progress, executives tell a crowd of analysts at JP Morgan,
You may also be interested in...
Most of the additional money will help support two trials – one for insulin as a treatment and one for crenezumab as a preventative. The Obama administration formally launched its national Alzheimer’s plan in the midst of a two-day meeting that underscored how little researchers know about the disease.
Launch news was an important factor for Bristol-Myers in the first quarter and dominated the biotech sector, with several companies reporting better-than-expected early performances of new products, although for Lilly, the news was all about upcoming data read-outs.
Executives presenting at the Barclays Capital Healthcare Conference on March 13-14 discussed everything from early pipeline progress to launch performance.